Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Golidocitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Golidocitinib (DZD-4205) is under development for the treatment of non-small cell lung cancer and T cell lymphomas including peripheral T cell lymphoma, vascular immunoblast type (AITL), Anaplastic large cell type-ALK positive (ALCL ALK+), anaplastic large cell type-ALK negative (ALCL ALK-); enteropathy-associated T cell lymphoma (EATL), monomorphic epithelial intestinal T cell lymph Tumor (MEITL), NK/T cell lymphoma (NKTCL), liver 44 splenic T cell lymphoma (HSTCL), subcutaneous panniculitis-like T cell lymphoma (SPTCL), relapsed and refractory cutaneous T-cell lymphomas including granuloma fungoides (MF) or Sezary syndrome (SS) It is a small molecule which acts by targeting JAK 1. It is administered through oral route.
Dizal (Jiangsu) Pharmaceutical overview
Dizal (Jiangsu) Pharmaceutical, a pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. The company is headquartered in China.
For a complete picture of Golidocitinib’s drug-specific PTSR and LoA scores, buy the report here.